Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.
CUH neurosurgeon wins prestigious Hunterian Professorship award
A consultant neurosurgeon from Addenbrooke’s Hospital has been given a prestigious award for his cutting-edge research into traumatic brain injury.
Tom’s Trust spread Christmas cheer to children in hospital
From superhero capes to books and cuddly soft toys, children were treated to some wonderful gifts from Tom’s Trust while spending time in hospital over the Christmas period.
The year in review: Updates and trends
In 2022, everyone witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues, breaches of distribution contracts and increasingly arbitrations deriving from geopolitical issues in Europe and Asia and from com
Arecor announces transfer of AT307 to Hikma
License milestone to develop and commercialise ready-to-use medicine achieved. Arecor regains rights to AT282 following portfolio review at Hikma.
Pheno Therapeutics announces worldwide license from UCB to a novel program for neurodegenerative disease
Preclinical program with potential for disease modifying therapeutic
FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production
Chemically defined, BalanCD HEK293 Viral Feed enhances viral vector production for gene therapy applications and viral vector-based vaccines
Local Employee Benefit Consultancy EBCam Ltd launches their 2023 survey to help companies benchmark their reward offering.
Specialist Employee Benefit consultancy EBcam Ltd, who are based out of Cambridge and Bury St Edmunds have re-launched their own employee benefit survey for 2023. The survey is free for local companies to participate in.
Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that it has entered into a strategic, multi-phase collaboration with the Instituto de Biologia Experim
2023: a new year with a renewed focus for the Guardtech Group
Cleanroom construction specialists’ multi-faceted approach set to reach new levels and new audiences in 2023.
Astrea Bioseparations acquires Delta Precision Ltd, a leading manufacturer of chromatography columns for biomanufacturing
Cambridge, UK - Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd.
Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board
Leading expert in DUB biology and drug discovery further strengthens Ubiquigent’s DUB-focused capabilities and internal pipelineDundee, UK - Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB)
Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs
Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines.
PhoreMost reaches milestone in a Target Discovery Alliance with Boehringer Ingelheim
PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.
Spatial lung cell atlas offers insights into disease and immune function
The most comprehensive lung cell atlas to date, from the Wellcome Sanger Institute and collaborators, has revealed 11 new lung cell types and offers detailed insight into an immune process involved in fighting lung infections.
Cambridge health technology consultancy gears for growth with new hires
Health Tech Enterprise (HTE), a Cambridge-based health technology consultancy, has expanded its team with two strategic new hires, marking a period of ongoing growth for the company.
Cambridge Healthcare Research reveals new brand identities to support its ambitious growth trajectory
Cambridge Healthcare Research has unveiled an extensive rebrand across its divisions. The rebrand includes a move to a house of brands model and sees the competitive intelligence arm of the business renamed and reimagined as Solici.
IHT receipts rise again
HMRC has published details of tax receipts for April to November 2022- A tax paid by people hate relatives more than the tax man !
Supplement advice for New Year vegans
An expert group co-founded by an Addenbrooke’s clinician has issued a “cautionary message” to those thinking of moving to a plant-based diet this January.
Taking the Sting out of Vaccines
Cast your mind into the future and imagine the world in the grips of the next global respiratory pandemic. We have the monumental task of vaccinating the world against a novel pathogen. How should we achieve this?
Robot-assisted surgical trends in 2023 and beyond
Robotic-assisted surgery has been making its way into the operating room (OR) for decades, boosting minimally invasive general surgery, enhancing orthopaedics, and enabling precision-guided catheter systems—with continued improvements leading to complex systems such as Intuitive’s market-leading da Vinci. The benefits of these systems are widely accepted: articulated tools and HD cameras provide…
Mission Street lodges plans for £100m Oxford R&D hub
Scheme is to provide 182,900 sq ft of science and innovation workspace
MPs addressed on importance of sensory loss survey
Westminster hears plans for inaugural assessment of UK’s vision and hearing health
Rare Disease: A year in review
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown.